| Drug Name: | Spiramycin (24916-50-5) |
|---|---|
| PubChem ID: | 6602308 |
| SMILES: | C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)O)N(C)C)O)CC=O)C)OC4CC[C@@H]([C@H](O4)C)N(C)C |
| InchiKey: | ACTOXUHEUCPTEW-PAHZGSOZSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 843.065 |
| LogP | : | 2.3251 |
| Ring Count | : | 0 |
| Hydrogen Bond Acceptor Count | : | 16 |
| Hydrogen Bond Donor Count | : | 4 |
| Total Polar Surface Area | : | 195.38 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Carbidopa (28860-95-9) | Reduces The Antiparkinsonian Effects | Antagonistic | spiramycin markedly reduces the absorption of carbidopa, possibly by forming a non-absorbable complex in the gut or by accelerating its transit through the gut | Effect of a macrolide (spiramycin) on the pharmacokinetics of L-dopa and carbidopa in healthy volunteers |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category
| Toxicity | Source |
|---|